Dosing initiated for Pfizer's antiviral COVID-19 pill


Pfizer announced it has initiated dosing for its Phase 2/3 trial of its oral antiviral treatment against COVID-19 in 1,140 symptomatic, nonhospitalized adults. The candidate, PF-07321332, is being tested in combination with ritonavir.

Full story:

AIChE SmartBrief

Chemical engineering news

Designed specifically for chemical engineers, AIChE SmartBrief is a FREE weekly e-mail newsletter. It helps chemical engineers stay informed on the business and technology developments affecting our profession.